Permanent URL to this publication: http://dx.doi.org/10.5167/uzh-34566
Rudin, C; Wolbers, M; Nadal, D; Rickenbach, M; Bucher, H C (2010). Long-term safety and effectiveness of lopinavir/ritonavir in antiretroviral-experienced HIV-1-infected children. Archives of Disease in Childhood, 95(6):478-481.
AIM: To evaluate the long-term safety and effectiveness of lopinavir/ritonavir (LPV/r) in a population-based cohort of HIV-1-infected children. METHODS: All children enrolled in the Swiss Mother and Child HIV Cohort Study, treated with LPV/r-based combination antiretroviral treatment (cART) between November 2000 and October 2008, were included. RESULTS: 88 children (25 (28%) protease inhibitor (PI)-naive, 16 (18%) ART-naive) were analysed (251 patient-years on LPV/r). After 48 weeks on LPV/r, 70 children had a median (interquartile range (IQR)) decrease in HIV-1 viral load of 4.25 log (5.45-3.17; PI-naive, n=17) and 2.53 (3.68-1.38; PI-experienced, n=53). Median (IQR) increase in CD4 count was 429 (203-593; PI-naive) and 177 (21-331; PI-experienced) cells/microl. These effects remained stable throughout 192 weeks for 25 children. Treatment was stopped for viral rebound in seven and suspected toxicity in 12 children. CONCLUSION: Long-term treatment with LPV/r-based cART is safe and effective in HIV-1-infected children.
|Item Type:||Journal Article, refereed, original work|
|Communities & Collections:||04 Faculty of Medicine > University Children's Hospital Zurich > Medical Clinic|
|DDC:||610 Medicine & health|
|Deposited On:||06 Jul 2010 23:39|
|Last Modified:||27 Nov 2013 18:29|
|Publisher:||BMJ Publishing Group|
|Additional Information:||This article has been accepted for publication in Arch Dis Child 2010;95:478-481 following peer review and can also be viewed on the journal’s website at http://adc.bmj.com/|
|Citations:||Web of Science®. Times cited: 3|
Users (please log in): suggest update or correction for this item
Repository Staff Only: item control page